

8 January 2025

**Privatisation by way of merger**

**Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc.**

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

<b>Party</b>	<b>Date</b>	<b>Purchase / Sale</b>	<b>Number of shares</b>	<b>Price per share</b>	<b>Resultant balance (including those of any person with whom there is an agreement or understanding)</b>	<b>Percentage of class (including those of any person with whom there is an agreement or understanding)</b>
Lin Lijun	8 January 2025	Purchase	81,700	\$23.4977	12,417,084	7.5979%

End

Note:

Lin Lijun is a Class (6) associate connected with the Offeree company.

Dealings were made for his own account.

Mr. Lin Lijun, through controlled corporations, is interested in 4,200,000 domestic shares of Shanghai Henlius Biotech, Inc. (the Company), representing approximately 1.11 per cent of the total issued domestic shares of the Company.